JFK125R represents refractory, KRASG12D-driven B-ALL, PDX2 harbors the BCR-ABL1 translocation and IKZF1-deletion, and BLQ5 was derived from a relapsed BCR-ABL1+ B-ALL patient after treatment with imatinib [23]. Here, IKZF1 is linked to acute lymphoblastic leukemia.